IKAROS in Acute Leukemia: A Positive Influencer or a Mean Hater?
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24043282 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Maria Rosa Conserva und 13 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Section, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari 'Aldo Moro', 70124 Bari, Italy. Hauptthemen laut MEDLINE: Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 176 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
One key process that controls leukemogenesis is the regulation of oncogenic gene expression by transcription factors acting as tumor suppressors. Understanding this intricate mechanism is crucial to elucidating leukemia pathophysiology and discovering new targeted treatments. In this review, we make a brief overview of the physiological role of IKAROS and the molecular pathway that contributes to acute leukemia pathogenesis through IKZF1 gene lesions. IKAROS is a zinc finger transcription factor of the Krüppel family that acts as the main character during hematopoiesis and leukemogenesis. It can activate or repress tumor suppressors or oncogenes, regulating the survival and proliferation of leukemic cells. More than 70% of Ph+ and Ph-like cases of acute lymphoblastic leukemia exhibit IKZF1 gene variants, which are linked to worse treatment outcomes in both childhood and adult B-cell precursor acute lymphoblastic leukemia. In the last few years, much evidence supporting IKAROS involvement in myeloid differentiation has been reported, suggesting that loss of IKZF1 might also be a determinant of oncogenesis in acute myeloid leukemia. Considering the complicated “social” network that IKAROS manages in hematopoietic cells, we aim to focus on its involvement and the numerous alterations of molecular pathways it can support in acute leukemias.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematology Section, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari 'Aldo Moro', 70124 Bari, Italy.
- School of Medicine, University of Bari 'Aldo Moro', 70124 Bari, Italy.
ORCID-Profile: Francesco Tarantini, Cosimo Cumbo, Nicoletta Coccaro, Crescenzio Francesco Minervini, Pellegrino Musto, Francesco Albano
Zitieren
APA
Conserva, M. R., Redavid, I., Anelli, L., Zagaria, A., Tarantini, F., Cumbo, C., Tota, G., Parciante, E., Coccaro, N., Minervini, C. F., Minervini, A., Specchia, G., Musto, P., & Albano, F. (2023). IKAROS in Acute Leukemia: A Positive Influencer or a Mean Hater?. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24043282
Vancouver
Conserva MR, Redavid I, Anelli L, Zagaria A, Tarantini F, Cumbo C, et al. IKAROS in Acute Leukemia: A Positive Influencer or a Mean Hater?. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24043282
BibTeX
@article{Conserva2023,
author = {Conserva, Maria Rosa and Redavid, Immacolata and Anelli, Luisa and Zagaria, Antonella and Tarantini, Francesco and Cumbo, Cosimo and Tota, Giuseppina and Parciante, Elisa and Coccaro, Nicoletta and Minervini, Crescenzio Francesco and Minervini, Angela and Specchia, Giorgina and Musto, Pellegrino and Albano, Francesco},
title = {IKAROS in Acute Leukemia: A Positive Influencer or a Mean Hater?},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24043282}
}
EUVIMED